Raymond James & Associates’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $188K | Buy |
34,884
+251
| +0.7% | +$1.35K | ﹤0.01% | 3634 |
|
|
2024
Q2 | $115K | Sell |
34,633
-1,391
| -4% | -$4.6K | ﹤0.01% | 3676 |
|
|
2024
Q1 | $118K | Buy |
36,024
+3,240
| +10% | +$10.6K | ﹤0.01% | 3679 |
|
|
2023
Q4 | $115K | Sell |
32,784
-18,267
| -36% | -$64.1K | ﹤0.01% | 3597 |
|
|
2023
Q3 | $341K | Sell |
51,051
-761
| -1% | -$5.08K | ﹤0.01% | 3103 |
|
|
2023
Q2 | $435K | Buy |
51,812
+24,970
| +93% | +$209K | ﹤0.01% | 3002 |
|
|
2023
Q1 | $267K | Buy |
26,842
+1,173
| +5% | +$11.6K | ﹤0.01% | 3281 |
|
|
2022
Q4 | $179K | Sell |
25,669
-1,380
| -5% | -$9.61K | ﹤0.01% | 3465 |
|
|
2022
Q3 | $144K | Sell |
27,049
-4,177
| -13% | -$22.2K | ﹤0.01% | 3505 |
|
|
2022
Q2 | $125K | Buy |
31,226
+4,920
| +19% | +$19.7K | ﹤0.01% | 3601 |
|
|
2022
Q1 | $117K | Buy |
26,306
+4,609
| +21% | +$20.5K | ﹤0.01% | 3742 |
|
|
2021
Q4 | $87K | Sell |
21,697
-24,150
| -53% | -$96.8K | ﹤0.01% | 3834 |
|
|
2021
Q3 | $403K | Sell |
45,847
-495
| -1% | -$4.35K | ﹤0.01% | 3204 |
|
|
2021
Q2 | $525K | Buy |
46,342
+24,042
| +108% | +$272K | ﹤0.01% | 3033 |
|
|
2021
Q1 | $265K | Sell |
22,300
-498
| -2% | -$5.92K | ﹤0.01% | 3411 |
|
|
2020
Q4 | $156K | Hold |
22,798
| – | – | ﹤0.01% | 3431 |
|
|
2020
Q3 | $169K | Buy |
22,798
+698
| +3% | +$5.17K | ﹤0.01% | 3243 |
|
|
2020
Q2 | $92K | Sell |
22,100
-2,500
| -10% | -$10.4K | ﹤0.01% | 3264 |
|
|
2020
Q1 | $61K | Buy |
24,600
+2,000
| +9% | +$4.96K | ﹤0.01% | 3259 |
|
|
2019
Q4 | $131K | Buy |
22,600
+400
| +2% | +$2.32K | ﹤0.01% | 3398 |
|
|
2019
Q3 | $117K | Buy |
22,200
+5,100
| +30% | +$26.9K | ﹤0.01% | 3336 |
|
|
2019
Q2 | $103K | Buy |
+17,100
| New | +$103K | ﹤0.01% | 3365 |
|